I change the title of the thread each time I update with a more current edit.
[edit add 9-5-23] Last time I checked less than 5% of the trials included zinc, which is the most important constituent of any COVID-19 treatment protocol. Nevertheless these stunning results were achieved in spite of that handicap:
https://c19ivm.org/
[edit add 6-28-23]
Convient listing of studies: https://c19ivm.org/meta.html#fig_fp [end edit]
[edit add 3-6-22] "209 ivermectin COVID studies, 161 peer reviewed, 98 comparing treatment and control groups."
https://c19ivermectin.com/https://c19ivermectin.com/#early [end edit]
[edit title 8-19-21] 112 studies, 70 peer reviewed [end edit]
[edit add 6-24-21]
Important irrefutable (just as the evidence based medicine is) meta analysis demonstrating the stunning efficacy of ivermectin in treatment of COVID-19:
Ivermectin for COVID-19: real-time meta analysis of 60 studies
https://ivmmeta.com/ [end edit]
[edit add 2-11-22]
"Ivermectin COVID-19 studies. 148 studies, 98 peer reviewed, 78 with results comparing treatment and control groups."https://c19ivermectin.com/ [end edit]
Ivermectin from our friends at c19. Listing 100% positive results for prophylaxis, early and late treatment with this also inexpensive ($20) protocol.
Click on the studies and follow links to "Source" to see the published study pages
pre-exposure prophylaxis
https://c19ivermectin.com/#prepearly treatment
https://c19ivermectin.com/#earlylate treatment
https://c19ivermectin.com/#latePlease go to the webpage at the following link instead of wasting time with the following copy and paste, as there are links that go directly to the study sources.
https://c19ivermectin.com/ (all)Examples:
1/16
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis) meta-analysis v20 Ivermectin is effective for COVID-19: real-time meta analysis of 32 studies
•
100% of the 50 studies to date report positive effects. Early treatment is more successful, with an estimated reduction of 85% in the effect measured using a random effects meta-analysis, RR 0.15 [0.06-0.37]. Prophylactic use also shows..
1/13
Early, Late, PrEP, PEP Kory et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.643369 (Review) (Peer Reviewed) review Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been widely used, showing efficacy of ivermectin in prophylaxis and treatment of COVID-19.
1/12
Late Okumuş et al., NCT04646109 (Preprint)
death, ↓33.3%, p=0.55 Ivermectin for Severe COVID-19 Management
Small RCT for severe COVID-19 comparing ivermectin with low dose HCQ+AZ+favipiravir, with 30 treatment and 30 control patients in Turkey, showing lower mortality and greater improvement at day 5.
1/11
PrEPPEP NCT04701710, Maria de los Angeles Peral de Bruno, Ministry of Public Health, Argentina (Preprint)
cases, ↓94.7%, p=0.003 Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc)
Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina with 234 healthcare workers showing significantly lower cases with treatment. No paper is available yet but results are reported on clinicaltrials.gov.
1/11
N/A Bousquet-Melou et al., Preprint, doi:10.22541/au.161047848.80388481/v1 (Preprint) dosing study Large Impact of obesity on the disposition of ivermectin, moxidectin and eprinomectin in a canine model: relevance for COVID-19 patients
Animal dosing study with an obese dog model concluding that ivermectin maintenance doses should be based on lean body weight and not the total body weight in obese subjects, while the loading dose should be based on the total body weight.
1/9
Early Kirti et al., medRxiv, doi:10.1101/2021.01.05.21249310 (Preprint)
death, ↓88.7%, p=0.12 Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial
RCT with 112 mild and moderate COVID-19 patients in India, showing lower mortality, ventilation, and ICU a
12/2
Early
Chamie, J. (News) news The effect of using ivermectin to control COVID-19 in Chiapas
After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has seen a dramatic divergence from other states with much lower mortality [1, 2].
https://twitter.com/jjchamie/status/133422858187093196812/1
Early
Alonso et al., (Preprint)
death, ↓91.8%, p=0.009 COVID-19: Uso de ivermectina
Observational study in Argentina showing significantly lower mortality in the 60 days after adopting ivermectin compared to the 60 days before, relative risk RR 0.082, p=0.003.
11/28
PrEP
Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231 (Peer Reviewed)
death, ↓99.4%, p=0.08 Ivermectin benefit: from scabies to COVID-19, an example of serendipity
69 residents of a French care home, median age 90, were treated with ivermectin for a scabies outbreak. 7 of 69 treated patients had probable or certain COVID-19, with no serious cases and no deaths. In comparable care homes in the same ..11/28
PrEP
Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248 (Peer Reviewed)
cases, ↓78.0%, p<0.02 A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin
Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases.
11/24
Late Niaee et al., Research Square, doi:10.21203/rs.3.rs-109670/v1 (Preprint)
death, ↓81.8%, p=0.001 Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
82% lower mortality with ivermectin. RCT with 180 hospitalized patients showing reduced mortality and hospital stay with ivermectin, with a wide margin of safety. All patients received SOC including low dose HC Q.
11/22
Animal
de Melo et al., bioRxiv, doi:10.1101/2020.11.21.392639 (Preprint) animal study Anti-COVID-19 efficacy of ivermectin in the golden hamster
Hamster study finding significantly lower COVID-19 pathology although not finding lower viral load at the dosage used. Ivermectin dramatically reduced the Il-6/Il-10 ratio in lung tissue, which may account for the more favorable clinical ..
11/18
Late Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223 (Preprint)
death, ↓99.1%, p=0.04 Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience
Retrospective 976 hospitalized patients with 34 treated with ivermectin showing ivermectin mortality relative risk RR 0.13, p = 0.04.
11/17
PrEP
Carvallo et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007 (Peer Reviewed)
cases, ↓99.9%, p<0.0001 Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel
Prophylaxis study using ivermectin and carrageenan showing 0 of 788 cases from treated healthcare workers, compared to 237 of 407 control.11/14
Late Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed)
recov. time, ↓21.1%, p=0.03 Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2
100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment.
11/13
PEP
Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v1 (Preprint)
cases, ↓80.0%, p=0.03 Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
RCT for prophylaxis with ivermectin showing a significant reduction in cases with treatment. Relative risk of COVID-19 case RR 0.2, p = 0.03 This paper also reports a treatment study [1].
11/13
Late Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v1 (Preprint)
death, ↓91.7%, p<0.0001 Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
RCT comparing ivermectin + SOC vs. HC Q + SOC, showing a significant reduction in mortality with ivermectin. Mortality relative risk: RR 0.11, p = 0.12 (mild/moderate cases) RR 0.1, p < 0.001 (severe cases) The HC<..
11/11
Late Camprubí et al., PLoS ONE, 15:11, doi:10.1371/journal.pone.0242184 (Peer Reviewed)
ICU, ↓33.3%, p=1.00 Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Tiny 26 patients retrospective study of ivermectin 200 μg/kg, median 12 days after symptoms, not showing significant differences. Authors suggest the dose is too low and recommend evaluation of higher doses. All patients received HC
11/11
Early
Krolewiecki et al., SSRN (Preprint) Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial
Viral load RCT finding a concentration dependent antiviral activity of oral high dose ivermectin at a dosing regimen that is well tolerated. There was no significant difference in viral load reduction between groups overall, but a signif..
11/10
Review
Turkia, M., ResearchGate (Review) (Preprint) review FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 — a brief review
Review suggesting ivermectin should be used based on existing data suggesting significant benefits, and that waiting for additional data may result in significant harm.
11/4
Early
Cadegiani et al., medRxiv, doi:10.1101/2020.10.31.20223883 (Preprint)
death, ↓78.3%, p=0.50 Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxych loroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated ..
11/3
Early, Late Morgenstern et al., medRxiv, doi:10.1101/2020.10.29.20222505 (Preprint) The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020
Retrospective 3,099 patients, all receiving ivermectin. Of 2,706 outpatients, there was only 18 hospitalizations, 2 ICU admissions, and 1 death. Of 300 hospitalized patients with moderate cases, 3 died. Of 111 ICU patients, 34 died.11/3
PrEP
Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint)
cases, ↓49.7%, p<0.0001 Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study
Retrospective prophylaxis study for HC Q, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin. HC
11/2
Animal
Arévalo et al., bioRxiv, doi:10.1101/2020.11.02.363242 (Preprint) animal study Ivermectin reduces coronavirus infection in vivo: a mouse experimental model
Mouse study showing ivermectin reducing MHV viral load and disease. MHV is a type 2 family RNA coronavirus similar to SARS-CoV2.
10/26
Late Hashim et al., medRxiv, doi:10.1101/2020.10.26.20219345 (Preprint)
death, ↓66.7%, p=0.27 Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
RCT 70 ivermectin-doxycycline patients and 70 control patients showing reduced time to recovery and reduced mortality with treatment. The earlier ivermectin+doxycycline was administered, the higher rate of successful therapy.
10/22
PrEP
Guerrero et al., Colombia Médica, doi:10.25100/cm.v51i4.4613 (Peer Reviewed) COVID-19: The Ivermectin African Enigma
Study of African Programme for Onchocerciasis Control (APOC) countries, which used ivermectin, with non-APOC countries in Africa, showing 28% lower mortality for APOC countries, relative risk RR = 0.72 [0.67-0.78].
10/13
Late Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009 (Peer Reviewed)
death, ↓46.0%, p=0.04 Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%), propensity matched odds ratio OR 0.47 [0.22-0.99], p=0.045.
10/9
Late Mahmud et al., Clinical Trial Results, NCT04523831 (Preprint)
death, ↓85.8%, p=0.12 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. There is no paper yet, results are reported on clinicaltrials.gov. 183 treatment and 180 control patients. Treatment delay is n..
10/8
Theory
Francés-Monerris et al., ChemRxiv, doi:10.26434/chemrxiv.12782258.v1 (Preprint) (Theory) theory Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent
In silico study showing that ivermectin is capable of interfering in different key steps of the SARS-CoV-2 replication cycle.
10/8
Late Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066 (Preprint)
death, ↓17.1%, p=0.01 Real-World Effectiveness of hydroxych loroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru
Retrospective database study of 5683 patients, 692 received HC Q/C Q+AZ, 200 received HC Q/C Q, 203 received ivermectin, 1600 received AZ, 358 receive..
9/30
Late Chachar et al., International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378 (Peer Reviewed)
no recov., ↓10.0%, p=0.50 Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Small RCT with 25 ivermectin and 25 control patients, not finding a significant difference in recovery at day 7.
9/24
Late
Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter)
death, ↓87.0%, p<0.05 Ivermectin treatment may improve the prognosis of patients with COVID-19
Retrospective 115 ivermectin patients and 133 control patients showing significantly lower death and faster viral clearance. Some potential issues can be found in [1].
9/22
N/A
Li et al., J. Cellular Physiology, doi:10.1002/jcp.30055 (Peer Reviewed) in vitro Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
In Vitro study showing Ivermectin is a safe wide-spectrum antiviral against SARS-CoV-2, human papillomavirus (HPV), Epstein–Barr virus (EBV), and HIV. Authors note that the combination of ivermectin and other drugs might result in more f..
9/15
Early
Carvallo et al., medRxiv, doi:10.1101/2020.09.10.20191619 (Preprint)
death, ↓87.9%, p=0.05 Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin. There was one death from 167 patients for 0.59% mortality, compared to an estimated overall mortality rate in Argentina of 2.1%. For moderate to severe cases needi..
9/15
Review
Jans et al., Cells 2020, 9:9, 2100, doi:10.3390/cells9092100 (Review) (Letter) review Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2. Cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, V..9/3
Late Podder et al., IMC J. Med. Science, 14:2, July 2020 (Peer Reviewed)
recov. time, ↓16.1%, p=0.34 Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study
Small RCT with 32 ivermectin patients and 30 control patients. The mean recovery time after enrolment in the intervention arm was 5.31 ± 2.48 days vs. 6.33 ± 4.23 days in the control arm, p > 0.05. Negative PCR results were not signific..
8/28
PEP
Shouman et al., NCT04422561 (Preprint)
symp. case, ↓91.3%, p<0.001 Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19
PEP trial for asymptomatic close contacts of COVID-19 patients, 203 ivermectin patients and 101 control patients. 7.4% of contacts developed COVID-19 in the ivermectin group vs. 58.4% in the control group, adjusted odds ratio OR 0.087, p ..
8/15
Early
Espitia-Hernandez et al., Biomedical Research, 31:5 (Peer Reviewed)
viral+, ↓97.2%, p<0.0001 Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study
Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients. All treated patients were PCR- at day 10 while all control patients remained PCR+. The mean duration of symptoms was 3 days in the treatm..
8/14
Late Bhattacharya et al., medRxiv, doi:10.1101/2020.08.12.20170282 (Peer Reviewed) Observational Study on Clinical Features, Treatment and Outcome of COVID 19 in a tertiary care Centre in India- a retrospective case series
Retrospective 148 hospitalized patients showing triple therapy with ivermectin + atorvastatin + N-acetylcysteine resulted in a 1.35% case fatality rate which was well below the national average.
7/31
Theory
Chang et al., ResearchGate (Preprint) (Theory) theory COVID-19: Post-exposure prophylaxis with ivermectin in contacts. At Homes, Places of Work, Nursing Homes, Prisons, and Others
Proposed PEP protocol based on ivermectin.
7/31
Late Alam et al., Journal of Bangladesh College of Physicians and Surgeons, doi:10.3329/jbcps.v38i0.47512 (Peer Reviewed) A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline
Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, deaths, or serious side effects reported.
7/31
Late Rahman et al., J. Bangladesh Coll. Phys. Surg. 38, 5-9, doi:10.3329/jbcps.v38i0 (Peer Reviewed) Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxych loroquine with Azithromycin in COVID-19 Patients
Comparison of 200 patients treated with ivermectin + doxycycline and 200 treated with HC Q + AZ. The HC Q + AZ group had more severe cases at baseline. Viral clearance was faster with ivermectin..
7/14
Early
Chowdhury et al., Research Square, doi:10.21203/rs.3.rs-38896/v1 (Preprint) A Randomized Trial of Ivermectin-Doxycycline and Hydroxych loroquine-Azithromycin therapy on COVID19 patients
Small 116 patient RCT comparing Ivermectin-Doxycycline and HC Q+AZ, not showing a significant difference in time to PCR negative or symptom resolution. Time to symptomatic recovery was 5.93 days for Ivermectin-Doxycy..
7/8
Late Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979 (Preprint)
death, ↓71.0%, p=1.00 Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Small trial of hospitalized patients with 16 of 87 patients being treated with ivermectin showing a significantly lower mean hospital stay with ivermectin: 7.62 vs. 13.22 days, p=0.00005. 0 of 16 ivermectin patients died vs. 2 of 71 cont..
6/30
N/A
Caly et al., Antiviral Research, doi:10.1016/j.antiviral.2020.104787 (Peer Reviewed) in vitro The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
In Vitro study showing that ivermectin is an inhibitor of SARS-CoV-2, with a single addition to Vero-hSLAM cells 2h post infection with SARS-CoV-2 able to effect ~
5000-fold reduction in viral RNA at 48h.
6/19
Theory
Lehrer et al., In Vivo, 34:5, 3023-3026, doi:10.21873/invivo.12134 (Theory) theory Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
In silico analysis showing ivermectin docking which may interfere with the attachment of the spike to the human cell membrane.
6/12
Review
Heidary et al., The Journal of Antibiotics, 73, 593–602, doi:10.1038/s41429-020-0336-z (Review) (Peer Reviewed) review Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
Review of the antimicrobial, antiviral, and anti-cancer properties of
ivermectin. Antiviral effects have been reported for Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki For..
5/2
Early
Chang, G., Research Gate, doi:10.13140/RG.2.2.34689.48482/7 (Preprint) Inclusión de la ivermectina en la primera línea de acción terapéutica para COVID-19
Peru observational case study of 7 patients treated with ivermectin, showing improvement and resolution of fever
https://www.goodrx.com/ivermectin
